MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$34,659K
EPS
-$0.17
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
-
-
0
-
Research and development
19,595
-
19,702
22,526
General and administrative
5,787
-
955
6,835
Impairment of long-lived assets
-
-
0
6,763
Loss on lease component termination
-11,145
-
-
-
Total operating expenses
36,527
-
20,657
36,124
Income (loss) from operations
-36,527
-
-20,657
-36,124
Interest income
1,982
-
1,309
1,605
Other income (loss)
-5
-
103
97
Total other income
1,977
-
1,412
1,702
Income (loss) before provision for income taxes
-34,550
-
-19,245
-34,422
Personnel and related costs
-
5,596
-
-
Facility and other allocated costs
-
3,468
-
-
Research and laboratory
-
7,468
-
-
Other research and development
-
573
-
-
General and administrative
-
6,579
-
-
(benefit) provision for income taxes
-
-
-68
-
Other segment (income) expense
-
-2,039
-
-
Net income (loss)
-34,550
-21,645
-19,177
-34,422
Unrealized loss on investments
-109
-615
-34
-19
Comprehensive income (loss)
-34,659
-22,260
-19,211
-34,441
Basic EPS
-0.17
-0.11
-0.22
-0.4
Diluted EPS
-0.17
-0.11
-0.22
-0.4
Basic Average Shares
205,778,156
193,474,913
87,502,722
86,464,066
Diluted Average Shares
205,778,156
193,474,913
87,425,291
86,464,066
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive income (loss)
-$34,659K
(-5.79%↓ Y/Y)
Net income (loss)
-$34,550K
(-6.17%↓ Y/Y)
Unrealized loss on
investments
-$109K
(50.90%↑ Y/Y)
Interest income
$1,982K
(-1.39%↓ Y/Y)
Income (loss) before
provision for income taxes
-$34,550K
(-6.17%↓ Y/Y)
Total other income
$1,977K
(-6.88%↓ Y/Y)
Other income (loss)
-$5K
(-104.42%↓ Y/Y)
Income (loss) from
operations
-$36,527K
(-5.37%↓ Y/Y)
Total operating
expenses
$36,527K
(5.37%↑ Y/Y)
Research and development
$19,595K
(-27.04%↓ Y/Y)
Loss on lease
component termination
-$11,145K
General and
administrative
$5,787K
(-25.86%↓ Y/Y)
Buy us a coffee
Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC)